Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 30 Dornase alfa

The TK aims to conclude discount contracts pursuant to Section 130a (8) SGB V with all suitable pharmaceutical companies for the active substance Dornase alfa. The contract is concluded under the TK's Open-House procedure: Individual negotiations on contract terms are not conducted, uniform conditions apply. The TK does not guarantee exclusivity to individual contracting partners. The contract period is a maximum of 24 months, starting on 01.01.2027. The contract ends at the latest on 31.12.2028, regardless of the date of contract conclusion. All further information can be found in the tender and contract documents.